๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Zhengzhou
Clinical trial register · China

Clinical Trials in Zhengzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Henan Cancer Hospital72 The First Affiliated Hospital of Zhengzhou University39 Merck Sharp & Dohme LLC27 AbbVie21 Novartis Pharmaceuticals20
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Zhengzhou

921 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Early Vitrectomy vs PRP in Early Proliferative Diabetic Retinopathy
NCT07586787Proliferative Diabetic Retinopathy (PDR)
Xiamen Ophthalmology Center Affiliated to Xiamen University
Not applicable
100
Beijing, Xiamen, Zhengzhou, Nanjing, Dalian
2025-01-01
Not yet open
A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
NCT06779461Hepatocellular Carcinoma Non-Resectable
InnoBM Pharmaceuticals Co., Ltd.
Phase 3
228
Bengbu, Anyang, Zhengzhou, Nanjing, Lishui, Guangzhou, Lanzhou, Luoyang
2025-01
Not yet open
Application of LARS Ligament in Bone Prosthesis Replacement
NCT05616182Malignant Tumor
Henan Cancer Hospital
Observational
100
Zhengzhou
2024-12-30
Active, closed
A Real-World Study on the Efficacy and Safety of Pradefovir Mesylate Tablets in the Treatment of Chronic Hepatitis B
NCT07555340HEPATITIS B CHRONIC
Juan Li
Observational
400
Zhengzhou
2024-12-30
Recruiting
An Exploratory Study on the Failure of Immunotherapy With Voronib Combined With Everolimus
NCT06730672Renal Cell Carcinoma Stage I
Sun Yat-sen University
Phase 2
80
Guangzhou, Zhengzhou
2024-12-30
Recruiting
Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
NCT06613009Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
190
Hefei, Fuzhou, Zhengzhou, Changsha, Nanchang, Jinan, Hangzhou
2024-12-30
Not yet open
Application of 3D Printed Prosthesis in Limb Salvage Surgery for Bone Tumors
NCT05616195Malignant Tumor
Henan Cancer Hospital
Observational
80
Zhengzhou
2024-12-28
Not yet open
Application of Antiosteoporosis Therapy in Osteolysis
NCT05617846Limb; Fusion, Complication
Henan Cancer Hospital
Observational
100
Zhengzhou
2024-12-28
Active, closed
Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy
NCT06743646Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Dystrophy
Chigenovo Co., Ltd
Phase 3
62
Beijing, Guangzhou, Haerbin, Zhengzhou, Shanghai, Chengdu, Tianjin, Wenzhou
2024-12-27
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Zhengzhou, Shanghai, Beijing, Guangzhou
2024-12-27
Active, closed
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522MTAP-deleted NSCLC
Amgen
Phase 2
61
Beijing, Fuzhou, Zhengzhou, Wuhan, Changsha, Changchun, Jinan, Shanghai
2024-12-26
Recruiting
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
NCT06643000Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation
Henan Cancer Hospital
Not applicable
60
Zhengzhou
2024-12-20
Recruiting
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
266
Hefei, Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-12-18
Recruiting
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
NCT06439342Cytomegalovirus (CMV)
Takeda
Phase 3
20
Hefei, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Beijing, Tianjin
2024-12-16
Recruiting
Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
NCT07028970Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
Observational
1,500
Beijing, Tianjin, Wuhan, Zhengzhou
2024-12-15
Recruiting
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
NCT06584032Advanced Endometrial Cancer
Hutchmed
Phase 3
412
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha
2024-12-12
Recruiting
Clinical Trial of TQB3002 in Patients With Advanced Cancers
NCT06662760Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
150
Guangzhou, Shenzhen, Zhengzhou, Nanjing, Nanchang, Shanghai, Xiโ€™an, Chengdu
2024-12-09
Recruiting
Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry
NCT06569095Myelodysplastic Syndromes
Peking University People's Hospital
Observational
163
Beijing, Wuhan, Zhengzhou
2024-12-09
Not yet open
Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).
NCT06654700Herpes Zoster
MAXVAX Biotechnology Limited Liability Company
Phase 3
1,200
Zhengzhou
2024-12-09
Recruiting
NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
NCT06781281Breast Cancer Invasive
Henan Cancer Hospital
Observational
709
Zhengzhou
2024-12-04
Recruiting
A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
NCT06930573HCC
The First Affiliated Hospital of Zhengzhou University
Phase 4
30
Zhengzhou
2024-12-04
Not yet open
Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer
NCT06670300Participants Who Had Received Second-line or Higher Advanced Melanoma and Advanced Renal Cancer
YongZhang
Phase 2
20
Zhengzhou
2024-12-01
Not yet open
CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
NCT06647329CAR-T Cell Therapy, Lymphomas
Mingzhi Zhang
Phase 1
30
Zhengzhou
2024-12-01
Not yet open
Clinical Study on the Treatment of Chronic Airway Diseases (Asthma, Chronic Obstructive Pulmonary Disease) with Shu Fei Tie
NCT06691802Chronic Obstructive Pulmoriary Disease (COPD), Asthma
Henan University of Traditional Chinese Medicine
Not applicable
2,312
Zhengzhou
2024-12
Not yet open
Safety and Efficacy of Perioperative Volume Replacement with Volulyte 6% in Moderate-to-high Cardiovascular Risk Patients Having Major Abdominal Surgery
NCT06663254Perioperative Volume Replacement, Hydroxyethyl Starch
Xiangya Hospital of Central South University
Phase 4
410
Zhengzhou, Changsha, Shenyang, Jinan, Xi'an, Beijing
2024-11-30
Recruiting
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
NCT06564324Non Small Cell Lung Cancer
Nuvation Bio Inc.
Phase 3
194
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Zhengzhou
2024-11-27
Recruiting
A Study of EH002 Gene Therapy for Otoferlin Gene Mutation-mediated Hearing Loss
NCT06722170DFNB9, Congenital Hearing Loss, Hearing Loss, Sensorineural
Yilai Shu
Not applicable
24
Zhengzhou, Shanghai
2024-11-22
Recruiting
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
NCT06959615Advanced Solid Tumor
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
334
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Langfang, Haerbin, Zhengzhou
2024-11-22
Recruiting
Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases
NCT06671236Amyotrophic Lateral Sclerosis (ALS)
Novabio Therapeutics
Phase 1
12
Zhengzhou
2024-11-21
Recruiting
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
NCT06666270Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Phase 1
30
Zhengzhou, Shanghai
2024-11-21
Recruiting
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
NCT06683885Newly Diagnosed Diffuse Large B-cell Lymphoma
Mingzhi Zhang
Phase 1/2
80
Zhengzhou
2024-11-20
Active, closed
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT06637501Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 2
94
Fuzhou, Zhengzhou, Changzhou, Nanjing, Shanghai, Hangzhou
2024-11-14
Recruiting
The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
NCT06452706Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
42
Bozhou, Chuzhou, Hefei, Maโ€™anshan, Wuhu, Harbin, Zhengzhou, Wuhan
2024-11-14
Recruiting
A Phase 2 Clinical Study of ABSK061 and ABSK043
NCT06632262HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
Abbisko Therapeutics Co, Ltd
Phase 2
202
Guiyang, Shijiazhuang, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan
2024-11-13
Active, closed
A Real-world Study to Assess Safety of OZURDEXยฎ (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China
NCT06548568Diabetic Macular Edema
AbbVie
Observational
110
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Dalian, Xi'an, Qingdao
2024-11-13
Active, closed
A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
NCT06297655Hemophilia A
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
60
Fuyang, Hefei, Chongqing, Lanzhou, Guangzhou, Nanning, Zhengzhou, Changsha
2024-11-12
Recruiting
An Observational Study of Coronary Microvascular Disease of China
NCT06676137Coronary Microvascular Disease
Henan Institute of Cardiovascular Epidemiology
Observational
500
Zhengzhou
2024-11-11
Recruiting
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
NCT06867991Anti-N-Methyl-D-Aspartate Receptor Encephalitis
The First People's Hospital of Changzhou
Phase 3
200
Zhengzhou, Changzhou
2024-11-08
Recruiting
A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation
NCT06667544KRAS G12D Mutation
Ranok Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
152
Nanning, Zhengzhou, Wuhan, Hangzhou, Shanghai
2024-11-08
By invitation
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
NCT06901622Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2
50
Zhengzhou
2024-11-08
Recruiting
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
NCT06817525Triple-negative Breast Cancer
Henan Cancer Hospital
Phase 2
64
Zhengzhou
2024-11-06
Active, closed
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT06601504Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hutchmed
Phase 2
61
Fuzhou, Guangzhou, Nanning, Wuhan, Harbin, Zhengzhou, Changsha, Nanchang
2024-11-05
Recruiting
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
NCT06596694Gastrointestinal Cancer
Merck Sharp & Dohme LLC
Phase 1/2
180
Hefei, Fuzhou, Xiamen, Guangzhou, Nanning, Zhengzhou, Shanghai, Taiyuan
2024-11-03
Recruiting
Longitudinal Cohort of Thrombosis and Hemostasis Diseases
NCT06727669Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura, Hemophilia A, Acquired, Disseminated Intravascular Coagulation
Peking University People's Hospital
Observational
3,000
Beijing, Zhengzhou, Chongqing
2024-11-01
Not yet open
Noninvasive Assessment of Pulmonary Fluid Levels by Remote Dielectric Sensing Technology to Improve Cardiac InsUfficieney During Ischemia-Reperfusion and Clinical Outcomes in MyocArdiaL Infarction
NCT06671067Acute Myocardial Infarction, Acute Decompensated Heart Failure (ADHF)
Shanghai 10th People's Hospital
Not applicable
2,000
Kaifeng, Zhengzhou, Shanghai
2024-11-01
Not yet open
Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation
NCT06704542ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus, Impaired Fasting Glucose
Ruijin Hospital
Observational
1,000
Zhengzhou, Wuhan, Shanghai, Hangzhou, Tianjin
2024-11
Not yet open
A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia
NCT06672263Chronic Myelogenous Leukemia
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
120
Beijing, Nanning, Zhengzhou, Shanghai, Hangzhou
2024-11
Not yet open
Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study
NCT06685354Hepatocellular Carcinoma (HCC)
Henan Cancer Hospital
Phase 2
11
Zhengzhou
2024-11
By invitation
Association of Nutritional Status With Immune Checkpoint Inhibitor Efficacy in Metastatic Metastatic Esophagogastric Cancer.
NCT06923020Gastric Neoplasm, Esophageal Adenosquamous Carcinoma
Yongxu Jia
Observational
200
Zhengzhou
2024-10-31
Active, closed
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
NCT06644768Non-small Cell Lung Cancer, Lung Cancer
Daiichi Sankyo
Phase 1/2
137
Changchun, Hangzhou, Harbin, Jiamusi, Shanghai, Tiyuan, Zhengzhou
2024-10-30
Not yet open
Current Status of Diagnosis and Treatment of Uroepithelial Carcinoma
NCT06663735Uroepithelial Carcinoma
The First Affiliated Hospital of Xinxiang Medical College
Observational
400
Kaifeng, Luoyang, Nanyang, Puyang, Xinxiang, Zhengzhou
2024-10-30
Recruiting
Evaluation of the Effectiveness and Safety of Laparoscopic Assisted Mastectomy With Preservation of Nipple and Areola, Immediate One-step Breast Reconstruction With Pectoral Muscle Prosthesis and Patch, and Simultaneous Autologous Fat Transplantation
NCT07037537Breast Cancer Patients
Henan Cancer Hospital
Not applicable
26
Zhengzhou
2024-10-30
Not yet open
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovyยฎ
NCT06633783Obesity
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Phase 3
370
Xuancheng, Huizhou, Luoyang, Nanyang, Zhengzhou, Yichang, Huaian, Lianyungang
2024-10-30
Recruiting
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
NCT06617715Pneumococcal Infectious Disease
Sinovac Life Sciences Co., Ltd.
Phase 3
3,080
Zhengzhou
2024-10-23
Recruiting
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779Metastatic Castration-Resistant Prostate Cancer
Pfizer
Phase 3
900
Wuhu, Beijing, Fuzhou, Guangzhou, Shantou, Guilin, Xinxiang, Zhengzhou
2024-10-22
Recruiting
A Study in Chinese Patients With Acquired Blepharoptosis
NCT06683651Blepharoptosis
Santen Pharmaceutical Co., Ltd.
Phase 3
180
Hefei, Beijing, Shantou, Guiyang, Zhengzhou, Haโ€™erbin, Wuhan, Xiangyang
2024-10-22
Recruiting
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
NCT06730373HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma
Qilu Hospital of Shandong University
Phase 2
110
Zhengzhou, Binzhou, Dongying, Jinan, Jining, Liaocheng, Linyi, Qingdao
2024-10-17
Not yet open
Phimumeยฎ Percutaneous Left Ventricular Assist System Study
NCT06639321Coronary Artery Disease
Shanghai NewMed Medical Co., Ltd.
Not applicable
250
Jilin City, Chengdu, Zhengzhou, Wuhan, Changsha, Shenyang
2024-10-14
Recruiting
A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma
NCT07599371Relapsed/Refractory Glioma
The First Affiliated Hospital of Zhengzhou University
Phase 1/2
29
Zhengzhou
2024-10-10
Recruiting
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06470048Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals
Phase 2
200
Nanning, Zhengzhou, Changchun, Chengdu, Ningbo, Beijing, Tianjin
2024-10-09
Recruiting
A Study of BG-C477 in Participants With Advanced Solid Tumors
NCT06596473Advanced Solid Tumors
BeOne Medicines
Phase 1
310
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou
2024-10-03
Not yet open
Respiratory Disease Cohort Studies of Chinese Medicine for COPD(RESEARCH-COPD)
NCT06577701Chronic Obstructive Pulmoriary Disease (COPD), Preserved Ratio Impaired Spirometry (PRISM)
Henan University of Traditional Chinese Medicine
Observational
10,000
Zhengzhou
2024-10-01
By invitation
Study on The Sensitizing Effect of Sonodynamic Therapy on The Treatment of Brainstem Glioma With Radiotherapy and Chemotherapy and Survival Analysis
NCT06999148Glioma (Any Grade) in the Brain
Yingjuan Zheng
Phase 2
216
Zhengzhou
2024-10-01
By invitation
Sonodynamic-Chemoradiotherapy Integration in Glioblastoma
NCT07130149Glioblastoma (GBM)
Yingjuan Zheng
Phase 2
230
Zhengzhou
2024-10-01
By invitation
Influencing Factors and Outcomes of DCB Angioplasty
NCT06620458Coronary Artery Disease
Henan Institute of Cardiovascular Epidemiology
Observational
5,000
Zhengzhou
2024-10-01
Not yet open
Twice-per-weekSelinexor, 2 Days Melphalan
NCT06613035Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
126
Shijiazhuang, Zhengzhou, Jinan, Chengdu
2024-09-30
Active, closed
Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer
NCT06464692Colorectal Cancer
AbbVie
Phase 1
31
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang, Hangzhou
2024-09-30
Recruiting
Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
NCT06609304Lymphoma, B-Cell
Zhengzhou University
Phase 4
20
Zhengzhou
2024-09-30
Recruiting
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
NCT06580301B-cell Acute Lymphoblastic Leukemia
Excyte Biopharma Ltd
Phase 1/2
46
Guangzhou, Guiyang, Zhengzhou, Xuzhou, Nanchang, Changchun, Dalian, Shenyang
2024-09-25
Not yet open
Cohort Study on the Treatment of Severe Pneumonia with Traditional Chinese Medicine
NCT06613659Community-Acquired Infections
Henan University of Traditional Chinese Medicine
Observational
1,016
Zhengzhou
2024-09-20
Recruiting
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT06469944Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Merck Sharp & Dohme LLC
Phase 1/2
160
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, รœrรผmqi, Hangzhou
2024-09-20
Not yet open
To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection
NCT06561594Idiopathic Hypogonadotropic Hypogonadism
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
60
Hefei, Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Nanchang
2024-09-20
Active, closed
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer
Amgen
Phase 1
49
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changchun, Chengdu, Beijing
2024-09-17
By invitation
An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine
NCT06484686Varicella
Sinovac (Dalian) Vaccine Technology Co., Ltd.
Phase 4
414
Zhengzhou
2024-09-16
Active, closed
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
NCT06487559Hepatocellular Carcinoma (HCC)
AbbVie
Phase 1
3
Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang
2024-09-11
Recruiting
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
NCT06631989EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Wayshine Biopharm, Inc.
Phase 1/2
100
Hefei, Beijing, Guangzhou, Zhengzhou, Jinan, Shanghai, Chengdu, Tianjin
2024-09-04
Recruiting
Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
NCT06572540Lung Cancer
Jiayuan Sun
Not applicable
110
Guangzhou, Zhengzhou, Shanghai, Chengdu, Hangzhou
2024-09-01
Recruiting
Energy CT in Imaging and Diagnosis of Gastric Cancer
NCT06869694Gastric Cancer, CT
The First Affiliated Hospital of Zhengzhou University
Observational
300
Zhengzhou
2024-09-01
Recruiting
"Selinexor+Pegaspargase+Dexamethasone"in โ… /โ…ก NKTCL
NCT06559553NKTCL, Selinexor
Mingzhi Zhang
Phase 1/2
50
Zhengzhou
2024-09-01
Active, closed
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
Servier Bio-Innovation LLC
Phase 1/2
48
Beijing, Harbin, Zhengzhou, Shenyang, Jinan, Shanghai, Hangzhou
2024-08-31
Active, closed
Volrustomig Priming Regimens Exploratory Phase II Platform Study
NCT06448754Non-small Cell Lung Cancer
AstraZeneca
Phase 2
194
Beijing, Hangzhou, Jinan, Yantai, Zhengzhou
2024-08-27
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897Atopic Dermatitis
AbbVie
Phase 3
675
Beijing, Yuzhong District, Xiamen, Shenzhen, Zhengzhou, Changsha, Dalian, Chengdu
2024-08-19
Recruiting
Genetically Modified T Cells Treating Malignant Tumors
NCT06515626Solid Tumor
Yi Zhang
Phase EARLY_PHASE1
100
Zhengzhou
2024-08-18
Recruiting
Evaluating the Feasibility of Bioresorbable Iron-Based Covered Stent: A Clinical Trial
NCT07316855Coarctation of the Aorta
Shubo Song
Not applicable
10
Zhengzhou
2024-08-16
Recruiting
Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
NCT07016724Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2
208
Zhengzhou
2024-08-15
Active, closed
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06508658Diffuse Large B-Cell Lymphoma
Genmab
Phase 3
379
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2024-08-13
Recruiting
Scoring Balloon and High Pressure Balloon in the Treatment of Arteriovenous Graft Stenosis
NCT06503692Arteriovenous Graft Stenosis
DK Medical Technology (Suzhou) Co., Ltd.
Not applicable
140
Beijing, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Shanghai
2024-08-13
Recruiting
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
NCT06615193Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
111
Zhengzhou, Suzhou, Xuzhou, Nanchang, Jinan, Hangzhou, Tianjing
2024-08-12
Recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534Crohn's Disease
AbbVie
Phase 3
110
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai, Hangzhou
2024-08-08
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Merck Sharp & Dohme LLC
Phase 1/2
210
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, รœrรผmqi, Hangzhou
2024-08-07
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Novartis Pharmaceuticals
Phase 2
84
Shijiazhuang, Zhengzhou, Beijing
2024-08-05
By invitation
Effects of ITBS Combined with NMES on Dysphagia After Stroke
NCT06464835Stroke, Dysphagia, Intermittent Theta Burst Stimulation, Neuromuscular Electrical Stimulation
The First Affiliated Hospital of Zhengzhou University
Not applicable
45
Zhengzhou
2024-08-03
By invitation
Effect of Theta Burst Transcranial Magnetic Stimulation on Patients with Dysphagia After Stroke
NCT06471309Stroke, Dysphagia, Functional Near- Infrared Spectroscopy, Transcranial Magnetic Stimulation
Zhang Xiaohui
Not applicable
45
Zhengzhou
2024-08-02
Recruiting
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
NCT06371157Hepatocellular Carcinoma
Akeso
Phase 3
469
Zhengzhou, Changsha, Nanjing, Hangzhou
2024-08-02
Not yet open
RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors
NCT06545201KRAS G12V, T Cell Therapy
Henan Cancer Hospital
Phase 1
30
Zhengzhou
2024-08-01
Not yet open
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer
NCT06554028Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms
Henan Cancer Hospital
Phase 2
46
Zhengzhou
2024-08
Recruiting
Clinical Trial of Pegylated Interferon ฮฑ-2b Via Nebulization for Treatment of Hand, Foot, and Mouth Disease .
NCT07008755HFMD
Zhengzhou Children's Hospital, China
Not applicable
90
Chengdu, Liangshan, Zhengzhou, Ziyang
2024-07-31
Recruiting
CPVI With Modified Linear Ablation Versus CPVI in Patients With Long-standing Persistent Atrial Fibrillation (SINUS)
NCT06516822Long-standing Persistent Atrial Fibrillation, Ablation
The First Affiliated Hospital with Nanjing Medical University
Not applicable
320
Beijing, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Dalian, Jinan, Xiโ€™an
2024-07-31
Recruiting
Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer
NCT07356531Liver Cancer
JIANGSU SHENMING Medical Technology CO., Ltd
Not applicable
216
Hefei, Beijing, Nanning, Guiyang, Shijiazhuang, Anyang, Luoyang, Zhengzhou
2024-07-29
Recruiting
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
NCT06386146Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
144
Beijing, Guangzhou, Zhengzhou, Shenyang, Jinan, Shanghai
2024-07-24
Rows per page Showing 401–500 of 921
Previous 3 4 5 6 7 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/zhengzhou?page=5

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 921 of those studies with a site in Zhengzhou.

How many clinical trials are recruiting in Zhengzhou?

553 of the 921 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 163 have not yet opened recruitment, 191 are active but closed to new participants, and 14 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.